Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Rapamycin
100%
Mantle Cell Lymphoma
100%
Telomerase Activity
100%
Bortezomib
100%
Cell Proliferation
20%
Lymphoma Patients
20%
Lymphoma Cells
20%
IC50
20%
Telomerase
20%
Novel Therapeutics
10%
Therapeutic Target
10%
Transcription Factor
10%
Protease Inhibitors
10%
Dose Effect
10%
Catalytic Subunit
10%
Incubation
10%
Combined Treatment
10%
Phosphorylation
10%
Synergistic Effect
10%
In Cancer
10%
Biochemical Mechanism
10%
Cancer Cells
10%
Malignant Cells
10%
Human Telomerase Reverse Transcriptase (hTERT)
10%
Therapeutic Potential
10%
Mononuclear Cells
10%
Growth Signaling
10%
Cellular Survival
10%
Pathway Inhibitors
10%
Signal Transduction Inhibitors
10%
Cytotoxic Effect
10%
Unfavorable Prognosis
10%
Pleiotropic Effects
10%
Differential Sensitivity
10%
Synergistic Inhibition
10%
Survival Pathways
10%
Therapeutic Combinations
10%
Proliferation Pathway
10%
Lymphoma Therapy
10%
Mechanism Reduction
10%
Pharmacology, Toxicology and Pharmaceutical Science
Rapamycin
100%
Telomerase
100%
Mantle Cell Lymphoma
100%
Bortezomib
100%
IC50
18%
Diseases
18%
Malignant Neoplasm
9%
Proteasome Inhibitor
9%
Protein Kinase B
9%
Transcription Factors
9%
Cytotoxicity
9%
Immunology and Microbiology
Sirolimus
100%
Lymphoma Cell
100%
Cell Proliferation
33%
IC50
33%
Cytotoxicity
16%
Enzyme Active Site
16%
Signal Transduction
16%
Transcription Factors
16%
Cancer Cell
16%
Mononuclear Cell
16%
Proteasome
16%
Cell Survival
16%
Mantle Cell Lymphoma Cell Line
16%
Mantle Cell Lymphoma Cell
16%
Neuroscience
Telomerase
100%
Bortezomib
100%
Sirolimus
100%
Cell Proliferation
18%
In Vivo
9%
In Vitro
9%
Cell Line
9%
Transcription Factors
9%
Enzyme Active Site
9%
Proteasome Inhibitor
9%
Cell Survival
9%
Cytotoxicity
9%
Protein Kinase B
9%
Signal Transduction Inhibitor
9%